How This Manufacturer Turned Big Pharma’s Commercialization Model Upside Down
When Pfizer (NYSE: PFE) acquired Biohaven Pharmaceutical Holding Company Ltd., the maker of a portfolio of calcitonin gene-related peptide (CGRP) receptor antagonists such as Nurtec ODT (rimegepant), for $11.6 billion, many big Pharma executives began to question their own beliefs and commercial…
#pfe #nurtec #vladcoric #pfizer #coric #clinicians #yaleuniversity #bristolmyerssquibb #bmy #yale